Skip to content
Screener

AbCellera Biologics Inc. ABCL Q1 2026 earnings

Reported May 11, 2026 · After market close

Revenue$8.3MBeat by $2.9M
EPS-$0.14Beat by $0.08
Revenue estimate$5.4M
EPS estimate-$0.22

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$5.3M
EPS estimate-$0.18

Financials

Q1 2026

Income statement

See full
Revenue$8.3M+96.3%
Operating income-$57.5M+8.2%
Net income-$43.2M+5.4%
EPS (diluted)-$0.14+6.7%

Balance sheet

See full
Cash & equivalents$102.1M-44.6%
Total debt$140.2M+107%
Total equity$938.1M-8.3%
Total assets$1.3B-2.8%

Cash flow

See full
Operating cash flow-$33.5M-190%
CapEx$3.8M-64.0%
Free cash flow-$37.4M-68.3%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$1.06B+59.2%
Enterprise value$1.1B+100.0%
P/S13.4×-15.4×

Profitability

See full
Operating margin-267.6%-120pp
Net margin-181.7%-77.9pp
FCF margin-238.9%-90.9pp

Returns & leverage

See full
Return on equity-14.7%-0.8pp
Debt / equity0.1×+0.1×
Current ratio14.1×+3.9×

Segments

By product

See full
Research fees$8.1M+99.7%
Licensing and royalty revenue$191.0K—

FAQ

When did AbCellera Biologics Inc. report Q1 2026 earnings?
AbCellera Biologics Inc. (ABCL) reported Q1 2026 earnings on May 11, 2026 after market close.
What were AbCellera Biologics Inc.'s Q1 2026 revenue and EPS?
AbCellera Biologics Inc. reported revenue of $8.3M and eps of $-0.14 for Q1 2026.
Did AbCellera Biologics Inc. beat estimates in Q1 2026?
Revenue beat the consensus estimate of $5.4M by $2.9M. EPS beat the consensus estimate of $-0.22 by $0.08.
How did AbCellera Biologics Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 96.3% from $4.2M a year earlier and eps grew 6.7% from $-0.15.
Where can I find AbCellera Biologics Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001703057-26-000027) and the 10-Q periodic report (0001703057-26-000028) directly on SEC EDGAR. The filing index links above go to sec.gov.